Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 9.


Berg, David D, Wiviott, Stephen D, Scirica, Benjamin M, Zelniker, Thomas A, Goodrich, Erica L, Jarolim, Petr, Mosenzon, Ofri, Cahn, Avivit, Bhatt, Deepak L, Leiter, Lawrence A
et al (show 8 more authors) (2021) A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. DIABETES CARE, 44 (11). pp. 2573-2581.


Zelniker, Thomas A, Wiviott, Stephen D, Raz, Itamar, Im, KyungAh, Goodrich, Erica L, Furtado, Remo HM, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit
et al (show 5 more authors) (2019) Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials. Circulation, 139 (17). pp. 2022-2031.


Bonaca, Marc P, Wiviott, Stephen D, Zelniker, Thomas A, Mosenzon, Ofri, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Goodrich, Erica L, De Mendonca Furtado, Remo Holanda, Wilding, John PH ORCID: 0000-0003-2839-8404
et al (show 8 more authors) (2020) Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation, 142 (8). pp. 734-747.


Mosenzon, Ofri, Raz, Itamar, Wiviott, Stephen D, Schechter, Meir, Goodrich, Erica L, Yanuv, Ilan, Rozenberg, Aliza, Murphy, Sabina A, Zelniker, Thomas A, Langkilde, Anna Maria
et al (show 11 more authors) (2022) Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial. DIABETES CARE, 45 (10). pp. 2350-2359.


Zelniker, Thomas A, Raz, Itamar, Mosenzon, Ofri, Dwyer, Jamie P, Heerspink, Hiddo HJL, Cahn, Avivit, Goodrich, Erica L, Im, Kyungah, Bhatt, Deepak L, Leiter, Lawrence A
et al (show 6 more authors) (2021) Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiology, 6 (7). pp. 801-810.


Kato, Eri T, Silverman, Michael G, Mosenzon, Ofri, Zelniker, Thomas A, Cahn, Avivit, Furtado, Remo HM, Kuder, Julia, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A
et al (show 13 more authors) (2019) Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. CIRCULATION, 139 (22). pp. 2528-2536.


Mosenzon, Ofri, Wiviott, Stephen D, Cahn, Avivit, Rozenberg, Aliza, Yanuv, Ilan, Goodrich, Erica L, Murphy, Sabina A, Heerspink, Hiddo JL, Zelniker, Thomas A, Dwyer, Jamie P
et al (show 11 more authors) (2019) Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. LANCET DIABETES & ENDOCRINOLOGY, 7 (8). pp. 606-617.


Schechter, Meir, Wiviott, Stephen, Raz, Itamar, Goodrich, Erica L, Rozenberg, Aliza, Yanuv, Ilan, Murphy, Sabina A, Zelniker, Thomas A, Fredriksson, Martin, Johansson, Peter A
et al (show 9 more authors) (2023) Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. LANCET DIABETES & ENDOCRINOLOGY, 11 (4). pp. 233-241.


Zelniker, Thomas A, Wiviott, Stephen D, Raz, Itamar, Im, Kyungah, Goodrich, Erica L, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit, Furtado, Remo HM
et al (show 5 more authors) (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. LANCET, 393 (10166). pp. 31-39.

This list was generated on Fri Oct 6 09:52:32 2023 BST.